MedSearchGraphRAG
6 quiz questions available for this topicTake Quiz

Palliative care - dyspnoea

SNOMED: 103735009928 words•Updated 03/03/2026
💡

Exam Tips

  • In OSCEs, start by assessing severity and function: ask about breathlessness at rest, speech limitation, sleep disturbance, and ability to wash/dress or climb stairs.
  • State explicitly that dyspnoea is subjective; do not dismiss severe symptoms because oxygen saturation is normal.
  • Use pattern recognition from history/exam to narrow causes (for example pleuritic pain plus unilateral signs suggests pleural pathology; stridor suggests upper airway obstruction).
  • Always mention parallel management: non-pharmacological measures, reversible-cause treatment, and low-dose opioid for refractory dyspnoea.
  • Safety marks: opioid titration with renal caution, benzodiazepine-opioid sedation risk, and oxygen mainly for hypoxaemia.
  • For revision visuals, use the CKS assessment tables of historical and examination clues as a bedside diagnostic framework (table-based figure substitute).

Definition

Dyspnoea in palliative care is the subjective experience of breathing discomfort (breathlessness), shaped by both physiological impairment and emotional response. It often reflects a mismatch between ventilatory demand and respiratory capacity, and in advanced illness it may persist even when objective tests are only mildly abnormal; anxiety commonly amplifies symptom severity and distress.

Pathophysiology

Breathlessness arises when respiratory drive increases (for example due to hypoxia, infection, metabolic acidosis, fever, anaemia, or anxiety) and/or ventilatory mechanics are impaired (airway obstruction, pleural effusion, parenchymal disease, respiratory muscle weakness, cardiac failure). Afferent signals from lungs/chest wall/chemoreceptors are integrated centrally; when expected ventilation cannot be achieved, the cortex perceives air hunger. In cancer, direct tumour effects (parenchymal involvement, lymphangitic spread, airway obstruction, pleural disease) and indirect effects (effusions, pulmonary embolism, treatment-related pneumonitis/fibrosis/cardiomyopathy, cachexia) commonly coexist, making dyspnoea multifactorial.

Risk Factors

  • Advanced cancer, especially primary lung cancer and metastatic thoracic disease
  • End-stage non-malignant disease (COPD, heart failure)
  • Pleural or pericardial effusion
  • Airway obstruction or stridor from tumour
  • Pulmonary embolism risk in malignancy/immobility
  • Anaemia and cachexia
  • Previous thoracic surgery, radiotherapy, or chemotherapy-related lung/cardiac toxicity
  • Anxiety, panic, fear, and psychosocial distress
  • Obesity, infection, and fever

Clinical Features

Symptoms

  • Progressive or episodic breathlessness (at rest or exertion)
  • Orthopnoea or breathlessness disturbing sleep
  • Reduced exercise tolerance (washing/dressing, stairs, walking distance)
  • Cough, sputum, wheeze, or haemoptysis
  • Pleuritic or central chest pain
  • Stridor, panic, or sensation of air hunger
  • Fatigue and impaired daily function

Signs

  • Tachypnoea, use of accessory muscles, shallow or laboured breathing
  • Cyanosis or low oxygen saturation (not always present in severe subjective dyspnoea)
  • Pallor (possible anaemia)
  • Localized reduced expansion, stony dullness and reduced breath sounds (pleural effusion pattern)
  • Hyper-resonance and reduced breath sounds (pneumothorax pattern)
  • Wheeze or silent chest (severe airflow obstruction)
  • Basal crackles (heart failure/pulmonary oedema)
  • Stridor (upper airway obstruction)
  • Plethora and distended neck/chest veins (possible SVC obstruction)
  • Normal chest examination with hyperventilation/panic phenotype

Investigations

Focused bedside assessment with symptom scale (e. g, 0-10 or visual analogue breathlessness score):Quantifies severity, functional impact, and response to treatment over time
Pulse oximetry:May show hypoxaemia; normal saturations do not exclude severe subjective dyspnoea
Chest X-ray:May identify pleural effusion, consolidation, collapse, pneumothorax, tumour burden, or pulmonary oedema
Full blood count:Anaemia or infection contributing to breathlessness
ECG (+/- troponin if clinically appropriate):Cardiac ischaemia, arrhythmia, or strain pattern when cardiac cause suspected
ABG/VBG in selected patients:Hypercapnia, hypoxaemia, or metabolic acidosis in severe/uncertain presentations
CT pulmonary angiography (if result would change management and aligns with goals of care):Pulmonary embolism
Point-of-care ultrasound/echocardiography where available:Pleural/pericardial effusion and cardiac dysfunction

Management

Lifestyle Modifications

  • Clarify goals of care and treat reversible causes where proportionate to prognosis and patient preference
  • Positioning (upright, forward-leaning), pacing, energy conservation, and occupational therapy advice
  • Cool airflow across face (handheld fan), calm environment, and breathing control techniques
  • Anxiety management: reassurance, brief psychological support, involve family/carers
  • Physiotherapy input for secretion clearance when appropriate
  • Advance care planning for recurrent/refractory episodes

Pharmacological Treatment

Opioids for refractory breathlessness

  • Morphine sulfate immediate-release oral 2.5 mg every 4 hours, plus 2.5 mg PRN; titrate cautiously
  • If unable to take oral: morphine sulfate subcutaneous 1-2 mg every 4 hours PRN (or via continuous infusion under specialist palliative guidance)

First-line drug approach for persistent refractory dyspnoea after non-pharmacological measures. Start low and review sedation, delirium, constipation, and nausea. Reduce dose and extend interval in renal impairment; consider alternatives (e. g, oxycodone) with specialist input. Avoid rapid escalation and monitor for respiratory depression.

Benzodiazepines (adjunct when anxiety/panic prominent or terminal distress)

  • Lorazepam 0.5-1 mg sublingual/oral PRN
  • Midazolam 2.5-5 mg subcutaneous PRN (or continuous infusion in end-of-life care under specialist supervision)

Not a replacement for opioids in chronic refractory dyspnoea but useful adjunct for severe anxiety-related breathlessness. Safety warnings: additive CNS/respiratory depression with opioids, falls risk, paradoxical agitation in some patients.

Oxygen therapy

  • Oxygen via nasal cannulae or mask, titrated to symptom relief when hypoxaemic

Use when there is documented or strongly suspected hypoxaemia; routine oxygen for non-hypoxaemic breathlessness is usually not beneficial. In CO2 retainers (e. g, advanced COPD), use controlled oxygen and monitor for hypercapnic deterioration.

Cause-directed pharmacotherapy

  • Salbutamol 100 micrograms per actuation inhaler, 1-2 puffs PRN (or nebulised 2.5-5 mg) for bronchospasm
  • Dexamethasone 4-8 mg once daily oral/subcutaneous for selected inflammatory or tumour-related airway/lymphangitic causes
  • Furosemide (e. g, 20-40 mg oral or IV) for fluid-overload/heart-failure phenotype
  • Antibiotics when bacterial infection is likely and treatment aligns with care goals
  • Anticoagulation for confirmed/suspected PE when benefits outweigh bleeding burden in context of prognosis

Tailor to likely reversible cause and patient priorities. Key contraindications/cautions: corticosteroids (hyperglycaemia, myopathy, delirium, infection risk), diuretics (AKI/electrolyte disturbance), anticoagulants (major bleeding risk, thrombocytopenia).

Surgical / Interventional

  • Therapeutic pleural aspiration or indwelling pleural catheter for recurrent malignant pleural effusion
  • Pleurodesis in selected patients with recurrent symptomatic effusion
  • Pericardiocentesis for symptomatic pericardial effusion/tamponade
  • Airway stenting or palliative radiotherapy for central airway obstruction (specialist MDT decision)
  • Thoracostomy for symptomatic pneumothorax when appropriate

Complications

  • Severe fatigue, insomnia, and reduced appetite
  • Anxiety, depression, fear, anger, helplessness, and social isolation
  • Loss of independence in ADLs (washing, dressing, mobility, communication)
  • Family role strain, relationship/intimacy difficulties, and financial/employment impact
  • Panic episodes and repeated emergency presentations
  • Reduced oral intake and deconditioning

Prognosis

Dyspnoea is very common in advanced illness and usually worsens with disease progression, particularly in late-stage cancer and end-stage cardiorespiratory disease. Prognosis depends on reversibility of contributing causes and overall trajectory: targeted treatment of effusions, infection, bronchospasm, anaemia, or heart failure may improve symptoms, but persistent refractory breathlessness often indicates high symptom burden and limited life expectancy, requiring anticipatory palliative planning.

Sources & References

💊BNF Drug References(21)

✅NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1786)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1784)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1777)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1790, 1791)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1827)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1781)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778, 1779)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 539, 540)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 548, 549)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 552)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 551, 552)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 550, 551)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 547)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 875)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8, 9)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 549, 550)[context]

Sources

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz